Uplizna™ (inebilizumab-cdon) – New orphan drug approval
June 11, 2020 - The FDA announced the approval of Viela Bio’s Uplizna (inebilizumab-cdon), for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Download PDF
